WOCKPHARMA Wockhardt Ltd Earnings Reports Announcement 2025 - Q3 Financial Results Wockhardt Ltd. reported a revenue growth of 8% to INR 2,290 Cr and EBITDA growth of 89% to INR 339 Cr for the nine months ended December 31, 2024, alongside positive results for its novel antibiotic Zaynich in a Phase III study..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Wockhardt Ltd